{"id":"NCT02504294","sponsor":"Pfizer","briefTitle":"A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis","officialTitle":"The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-13","primaryCompletion":"2016-07-02","completion":"2016-07-16","firstPosted":"2015-07-21","resultsPosted":"2018-06-13","lastUpdate":"2018-06-13"},"enrollment":432,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Chronic Kidney Disease (CKD)"],"interventions":[{"type":"BIOLOGICAL","name":"Epoetin Hospira Arm","otherNames":[]},{"type":"OTHER","name":"Standard of Care Arm","otherNames":[]},{"type":"DRUG","name":"IV Iron","otherNames":[]}],"arms":[{"label":"Epoetin Hospira","type":"OTHER"},{"label":"Standard of Care","type":"OTHER"}],"summary":"A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.","primaryOutcome":{"measure":"Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)","timeFrame":"Week 17 up to Week 24","effectByArm":[{"arm":"Epoetin Hospira","deltaMin":61.933,"sd":null},{"arm":"Epogen","deltaMin":63.3305,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["36791280","30196301"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":212},"commonTop":["Dyspnoea","Nausea"]}}